Johnson & Johnson on Friday said its single-shot coronavirus vaccine was 72% efficace nella prevenzione del COVID-19 da moderato a grave negli Stati Uniti, ma cadde a 66% in a larger trial conducted worldwide. The results stem from a Phase 3 ENSEMBLE clinical trial, which involved 43,783 partecipanti.
The shot was found to be 66% effective in preventing moderate-to-severe illness in Latin America, e 57% effective in South Africa at 28 days post-vaccination.
J&J’s vaccine differs from currently approved jabs in the U.S. in that it requires a single shot as opposed to two doses, and was created using an adenovirus rather than mRNA technology.
“Johnson & Johnson embarked on the global effort to combat the COVID-19 pandemic a year ago, and has brought the full force of our capabilities, as well as tremendous public-private partnerships, to enable the development of a single-shot vaccine. Our goal all along has been to create a simple, effective solution for the largest number of people possible, and to have maximum impact to help end the pandemic,” Alex Gorsky, Presidente, Board of Directors and Chief Executive Officer, Johnson & Johnson said in a press release Friday. “We’re proud to have reached this critical milestone and our commitment to address this global health crisis continues with urgency for everyone, ovunque.”
Questa è una storia in evoluzione. Ricontrolla per aggiornamenti.